Multifunctional ACE2-nanobody fusion design for pan-specific neutralization and cardiovascular protection in SARS coronavirus infection

Read full text Summarise with VIRAT
Authors: Traian I. Sulea, Matthew Stuible, M. Josefa Lopez Moreno, Alex Pelletier, Martín A. Rossotti, Yuneivy Cepero Donates, Jacqueline Slinn, Patrick Salois, Anh Tran, Melissa Hewitt, Álvaro Yogi, Nazanin Rohani
+8 more Brian Cass, Anne E.G. Lenferink, Jamshid Tanha, Binbing Ling, Etienne Lessard, Laurence Delafosse, Jagdeep K. Sandhu, Danica B Stanimirovic
Cited by: 0
References: 58

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

ABSTRACT Severe acute respiratory syndrome coronaviruses use the ACE2 receptor for viral entry while downregulating its activity, potentially leading to hypertension and major organ injuries. Dual-action technologies based on soluble ACE2 aimed to neutralize the virus while restoring ACE2’s normal enzymatic activity. Here, we describe a novel general molecular design, VHH Spike -ACE2 ECD -VHH Albumin , in the toolbox of ACE2-centric therapeutic modalities. The optimized nanobody module VHH Spike afforded strong pan-specific binding against the entire sarbecoviral clade. This correlated with potent in vitro neutralization of pseudotyped virus variants of concern, with IC 50 values in the picomolar range. Exogenous enzymatic activity was provided by the ACE2 ECD module, which also contributed binding avidity via intrinsic homodimerization. Persistence of enzymatic activity in circulation was increased in vivo via the nanobody module VHH Albumin optimized for serum albumin binding. Single-dose therapeutic administration of lead compound 72opt-ACE2-R28 demonstrated virus neutralization in lungs of hamsters at day 5 post-infection with SARS-CoV-2. In hypertensive mice maintained under continuous injection of angiotensin II, a single dose of 72opt-ACE2-R28 normalized systolic blood pressure, maintaining a 30 mmHg reduction after 24 h. Overall, encouraging coronavirus neutralization and hypertension reduction showed magnitudes and timeframes appropriate for treatment of typical acute infections. We discuss molecular bases of interactions with coronavirus spike protein molecules and future scale-up manufacturability toward clinical development of this modular design scaffold with high potential against emerging SARS-CoV-2 variants.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Monoclonal and Polyclonal Antibodies Research Animal Virus Infections Studies

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Volume
70
Issue
5
Pages
e0002426–e0002426
Publication date
23 March 2026
Language
EN